PMID- 25244188
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20220317
IS  - 1600-0714 (Electronic)
IS  - 0904-2512 (Linking)
VI  - 44
IP  - 6
DP  - 2015 Jul
TI  - Tumor progression driven by pathways activating matrix metalloproteinases and 
      their inhibitors.
PG  - 437-43
LID - 10.1111/jop.12270 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is still a problem 
      worldwide. In some publications interactions between the expression of matrix 
      metalloproteinases (MMPs), particularly MMP-2 and MMP-9, and their tissue 
      inhibitors (TIMPs) implicated during cancer progression were suggested. METHODS: 
      The immunohistochemical staining using primary antibody against MMP-2, MMP-9, 
      TIMP-1, TIMP-2, and TIMP-3 were performed. The research group consists of primary 
      N(0) LSCC (20 cases), primary N(+) LSCC (17 cases), and 18 cases of normal 
      mucosa. RESULTS: Studied MMPs and TIMPs were localized in tumor cells and tumor 
      stroma compartment. MMP-2 expression was higher in stroma compared to tumor 
      cells. MMP-9, TIMP-1, TIMP-2, and TIMP-3 expression was higher in tumor cells 
      than in tumor stroma (P < 0.05). In tumor stroma MMP-2, MMP-9, TIMP-1, and TIMP-3 
      expression, in LSCC N(0) vs. LSCC N(+) was significantly higher (P < 0.05). The 
      ratios between MMP-2 and TIMP-3 expression were statistically significant (N(0) 
      vs. N(+); P = 0.012). The analyses using classification trees predicted the 
      probability of metastases according to TIMP-3/MMP-14/MMP-2 and MMP-9/TIMP-1 
      expression levels. CONCLUSIONS: The presence of MMP-2, MMP-9, TIMP-1, TIMP-2, 
      TIMP-3 expression in tumor cells and in tumor stroma, and additionally different 
      expression according to lymph node involvement suggested of their impact during 
      cancer progression. The significant correlation between TIMP-3 expression and the 
      presence of lymph node metastases and MMP-2 expression might suggest the 
      importance of TIMP-3 as a prognostic factor during tumor progression. The 
      evaluation of molecular markers which participate in MMP-2 activation pathway 
      have a major impact during metastasis.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bodnar, Magdalena
AU  - Bodnar M
AD  - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus 
      Copernicus University, Bydgoszcz, Poland.
FAU - Szylberg, Lukasz
AU  - Szylberg L
AD  - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus 
      Copernicus University, Bydgoszcz, Poland.
FAU - Kazmierczak, Wojciech
AU  - Kazmierczak W
AD  - Department of Otolaryngology and Clinical Oncology Chair and Clinic of 
      Otolaryngology and Department of Pathophysiology of Hearing and Balance System, 
      Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, 
      Poland.
FAU - Marszalek, Andrzej
AU  - Marszalek A
AD  - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus 
      Copernicus University, Bydgoszcz, Poland.
AD  - Department of Oncologic Pathology, Poznan University of Medical Sciences and 
      Greater Poland Oncology Center, Poznan, Poland.
LA  - eng
PT  - Journal Article
DEP - 20140922
PL  - Denmark
TA  - J Oral Pathol Med
JT  - Journal of oral pathology & medicine : official publication of the International 
      Association of Oral Pathologists and the American Academy of Oral Pathology
JID - 8911934
RN  - 0 (TIMP1 protein, human)
RN  - 0 (TIMP2 protein, human)
RN  - 0 (TIMP3 protein, human)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-3)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*enzymology/*pathology
MH  - Female
MH  - Head and Neck Neoplasms/*enzymology/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*enzymology/*pathology
MH  - Lymph Nodes/enzymology/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Matrix Metalloproteinase 2/biosynthesis
MH  - Matrix Metalloproteinase 9/biosynthesis
MH  - Matrix Metalloproteinases/*biosynthesis
MH  - Middle Aged
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Tissue Inhibitor of Metalloproteinase-1/biosynthesis
MH  - Tissue Inhibitor of Metalloproteinase-2/biosynthesis
MH  - Tissue Inhibitor of Metalloproteinase-3/biosynthesis
MH  - Tissue Inhibitor of Metalloproteinases/*biosynthesis
OTO - NOTNLM
OT  - classification tree
OT  - laryngeal squamous cell carcinoma
OT  - matrix metalloproteinases
OT  - tissue inhibitors of matrix metalloproteinases
OT  - tumor microenvironment
EDAT- 2014/09/23 06:00
MHDA- 2016/08/16 06:00
CRDT- 2014/09/23 06:00
PHST- 2014/08/21 00:00 [accepted]
PHST- 2014/09/23 06:00 [entrez]
PHST- 2014/09/23 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
AID - 10.1111/jop.12270 [doi]
PST - ppublish
SO  - J Oral Pathol Med. 2015 Jul;44(6):437-43. doi: 10.1111/jop.12270. Epub 2014 Sep 
      22.